Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity

Apr 17, 2023 | Press Releases

– Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 – MARLBOROUGH, Mass., April 17, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™...

Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update

Mar 22, 2023 | Press Releases

– Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA that the planned Phase 1 clinical trial in patients...

Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer

Feb 22, 2023 | Press Releases

MARLBOROUGH, Mass., Feb. 22, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Feb 13, 2023 | Press Releases

MARLBOROUGH, Mass., Feb. 13, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...

Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Feb 10, 2023 | Press Releases

MARLBOROUGH, Mass., Feb. 10, 2023 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today...